Molecular Pathology Laboratory Network Inc. now offers evaluation of FGFR alterations for treatment of urothelial carcinoma with BALVERSA™ (erdafitinib)
On April 12, 2019 FDA approved Janssen’s Balversa™ (erdafitinib)…
Read more
San Diego June 27th is host to Dr. Tandon's workshop on contemporary genomic studies in hematologic pathology: Utility of next generation sequencing in clinical evaluation of myeloid and lymphoid malignancies.
Next generation sequencing…
Read more
You can view MPLN's Twitter Feed by clicking here @molpathnet
Molecular Pathology Laboratory Network, custom services for #oncologists #pathologists;
experience in #flowcytometry…
Read more
Myeloproliferative neoplasms (MPNs) are characterized by excess accumulation of one or more myeloid cell lineages and a tendency to transform to acute leukemia. Clinical data and practice guidelines have evolved at a rapid pace for this heterogeneous…
Read more
MPLN offers SP263 immunohistochemical testing for the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded tissue. PD-L1 expression level utilizing this clone has been associated with response to durvalumab (IMFINZI, AstraZeneca UK…
Read more